Perinatal exposure to antiretroviral agents: Risks and benefits

American Journal of Neuroradiology

Volumn 26, Issue 4, 2005, Pages 689-692

  Scott, Gwendolyn B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LACTIC ACID; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

CANCER; CESAREAN SECTION; CLINICAL TRIAL; CONGENITAL MALFORMATION; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INHIBITION; EDITORIAL; GROWTH DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT DISEASE; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; MYOPATHY; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PANCREAS DISEASE; PERINATAL DRUG EXPOSURE; PREGNANCY; PREMATURE LABOR; RISK ASSESSMENT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MITOCHONDRIAL ENCEPHALOMYOPATHIES; RISK FACTORS;

EID: 30544445585     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine treatment. N Eng J Med 1994;331:1173-1180
2. US Centers for Disease Control. Public Health Service recommendations on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43:1-20
3. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004 [http://AIDSinfo.nih.gov]
4. Stiehm ER, Lambert J, Mofenson L, et al. Efficacy of zidovudine and HIV hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999;179:567-575
5. Garcia PM, Kalish LA, Pitt J, et al. Maternal plasma HIV-1 RNA levels and risk of perinatal transmission. N Engl J Med 1999;341:394-402
6. Lindegren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282:531-538
7. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999;353:773-780
8. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-child transmission of HIV-1 in Kampala, Uganda: HIV-NET 012 randomized trial. Lancet 1999;354:795-802
9. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra Study): a randomized, double blind, placebo controlled trial. Lancet 2002;359:1178-1186
10. Culnane M, Fowler M, Lee SS, et al. Lack of long term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women: Pediatric AIDS Trials Group Protocol 219/076 Teams. JAMA 1999;281:151-157
11. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:463-467
12. Caselli D, Klersy C, de Martino M, et al. Human immunodeficiency virus-related cancer in children: incidence and treatment outcome: report of the Italian Register. J Clin Oncol 2000;18:3854-3861
13. Tuomala RE, Shapiro DE, Sorenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-1870
14. Blanche S, Tradieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089
15. Munnich A, Rotig A, Chretien, D., et al. Clinical presentation of mitochondrial disorders in childhood. J Inherit Metab Dis 1996;19:521-527
16. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-1785
17. Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25:261-268
18. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants: Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000;343:759-766
19. Brinkman K, Ter Hofstede HJ, Burger DM, et al. Adverse effects on reverse transcriptase inhibitors: mitochondrial toxicity as a common path way. AIDS 1998;12:1735-1744
20. Gerschenson M, Erhart SW, Paik CY, et al. Fetal mitochondrial heart and skeletal muscle damage in erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Human Retroviruses 2000;16:635-644
21. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal erythrocebus patas monkeys exposed transplacentally to zidovudine + lamivudine. AIDS Res Human Retroviruses 2004;20:91-100
22. Poirier MC, Dive RL, Al-Harti L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175-183
23. Alimenti A, Burge D, Ogilvie A, et al. Lactic academia in HIV infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003;22:782-789
24. The European Mode of Delivery Collaboration. Elective caesarian section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035-1039
25. Anonymous. ACOG Committee opinion: scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000. Int J Gynaecol Obstet 2001;73:279-281
26. Ioannidid JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001;183:539-545
27. Beasley RP, Hwang LY, Lee, GC-Y, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and Hepatitis B vaccine Lancet 1983;2:1099-1102
28. Centers for Disease Control. Protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1990;39:1-26
29. Mofenson L. Perinatal exposure to zidovudine: benefits and risks N Engl J Med 2000;343:803-805